학술논문
Management of Metastatic Urothelial Carcinoma in Emerging Markets (EM): An Expert Opinion.
Document Type
Academic Journal
Author
Soares A; Oncology and Hematology Center of Hospital Albert Einstein, Hospital Albert Einstein, Sao Paulo, Brazil. Electronic address: dr.andrey@uol.com.br.; Bourlon MT; Hemato-Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.; Wong A; Sr Consultant, Department of Haematology Oncology National University Cancer Institute, Singapore.; Joshi A; Professor, Medical Oncology, Tata Memorial Centre, HBNI, Mumbai, India.; Jardim D; Oncology Department, Oncoclínicas Institute, São Paulo, Brazil.; Korbenfeld E; Head of GU Tumors Unit, GU Tumors Unit, Hospital Británico de Buenos Aires, Buenos Aires, Argentina.; Karak FE; Hematology and Medical Oncology Service, University Medical Center Hôtel-Dieu De France Hospital, Faculty of Medicine, Saint Joseph University of Beirut, Lebanon.; Orlandi F; Medical Director, Orlandi Oncología Providencia, Chile.; Sze H; Specialist in Clinical Oncology, Heal Oncology Centre, Hong Kong, China.; Ansari J; Chief of Medical Oncology, Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates.; Zarba J; Medical Oncologist, Centro Médico San Roque, Tucumán, Argentina.; Mansour MA; Adult Medical Oncology, Princess Noorah Oncology Center, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.; Manneh R; edical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia.; Thirumulai R; Senior Consultant, Medical Oncology, Apollo Specialty Hospital, Chennai, India.; Tsai YC; Clinical Assistant Professor, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Morsi WA; GU & BSM Sr. Director Scientific Expert, Oncology Medical Affairs, Emerging Markets, Pfizer Ltd., Dubai, United Arab Emirates.; Powles T; Director of Barts Cancer Center, Professor of Urology Cancer, Barts Cancer Institute, London, United Kingdom.
Source
Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE
Subject
Language
English
Abstract
Urothelial carcinoma (UC) is the 10 th most common cancer globally with an almost 4 times higher prevalence in men. The main risk factors for development of urothelial carcinoma are advanced age, smoking, arsenic contamination, exposure to carcinogens. Metastatic urothelial carcinoma (mUC) has overall poor prognosis with a 5-year overall survival rate of only < 5%. The standard of care comprises of platinum-based chemotherapy, but the responses are often not sustained. A working group was established with an objective to discuss the most recent clinical data on the genitourinary tumors of interest and comprised of experts across Latin America, Emerging Asia (except China, Japan, and South Korea), Africa, and the Middle East (known as Emerging Markets or EM). There is an evident disparity in terms of uneven mortality and incidence rate distribution among various regions. There is a lack and/or insufficient data on epidemiology, treatment, and outcomes in the EM. The lack of registries impacts the healthcare decisions and the lower incidence from the region might not be reflective of the true disease burden. The treatment outcomes of mUC can be improved by understanding the current disease burden and treatment approach of mUC and identifying the gaps and challenges associated with management. Hence, a literature review was developed to summarize the current disease burden and treatment approach of mUC across EM. The review also highlights the unmet needs for mUC management in EM and suggests a way forward to improve the current situation in order to better serve the patients.
Competing Interests: Disclosure All authors are members of the Emerging Markets Genitourinary Cancer Working Group. Additionally, Waleed Al Morsi is a full-time employee of Pfizer.
(Copyright © 2024. Published by Elsevier Inc.)
Competing Interests: Disclosure All authors are members of the Emerging Markets Genitourinary Cancer Working Group. Additionally, Waleed Al Morsi is a full-time employee of Pfizer.
(Copyright © 2024. Published by Elsevier Inc.)